Branebrutinib - Bristol Myers Squibb
Alternative Names: BMS 986195Latest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Amides; Anti-inflammatories; Antirheumatics; Indoles; Piperidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
Most Recent Events
- 05 Dec 2022 Bristol-Myers Squibb completes a phase II trial in Systemic lupus erythematosus Sjögren's syndrome and Rheumatoid arthritis in USA, Argentina, Belgium, France, Germany, Mexico, Netherlands, Poland, Spain and United Kingdom (PO) (NCT04186871)
- 22 Aug 2022 Bristol-Myers Squibb completes a phase II trial in Atopic dermatitis in USA, Spain, Poland, Germany, Canada, Austria and Australia (PO) (NCT05014438) (EudraCT2020-004767-77)
- 01 Jun 2022 Safety and pharmacokinetics data from a phase I trials in healthy volunteers were presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)